Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757390 | 0.82 | ACHE (0.42) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL7173958 | 0.79 | ALDH1A1 (0.40) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL27584888 | 0.79 | ACHE (0.43) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL2471296 | 0.79 | ACHE (0.43) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL31088765 | 0.79 | ALDH1A1 (0.40) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL205989 | 0.78 | MAPT (0.36) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL15778376 | 0.78 | ALDH1A1 (0.55) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL29198744 | 0.78 | ALDH1A1 (0.45) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL6027776 | 0.77 | CA1 (0.42) | ACHEMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL28126392 | 0.77 | HSD17B10 (0.42) | ACHEMAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840532-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11793815-B2 | Oxindoles and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116802176-A | Oxindoles and methods of use thereof | 阿利戈斯治疗公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4240722-A1 | OXINDOLES AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4178672-A1 | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022099066-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220143031-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220009924-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-01-13 | — | — | US | disclosed |
| WO-2022011120-A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3842410-A1 | FIBRIC ACID COMPOUND AND MEDICAL USE THEREOF | Beijing Wholesomeyird Sci & Tech Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| CN-101180097-A | Novel phosphinic acid-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-14 | — | — | CN | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793815-B2 | Oxindoles and methods of use thereof | CYP11B2, OXTR, CYP11B1 | ACHE 413/4885MAPT 16/4885ALDH1A1 689/4885 |
| US-20220143031-A1 | OXINDOLES AND METHODS OF USE THEREOF | CYP11B2, OXTR, CYP11B1 | ACHE 413/4885MAPT 16/4885ALDH1A1 689/4885 |
| US-20220009924-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TTR | ACHE 1873/4885MAPT 6/4885ALDH1A1 3985/4885 |
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | ACHE 2032/4885MAPT 4392/4885ALDH1A1 1463/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | ACHE 2032/4885MAPT 4392/4885ALDH1A1 1463/4885 |
| US-11840532-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TTR | ACHE 2733/4885MAPT 7/4885ALDH1A1 4185/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | ACHE 2425/4885MAPT 3105/4885ALDH1A1 4147/4885 |
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | ACHE 2032/4885MAPT 4392/4885ALDH1A1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.